Clinical Trial Update: Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years [Phase 2]

View source ↗

Summary

A Phase 2 study of Clofarabine and low-dose Cytarabine followed by consolidation in patients with acute myeloid leukemia aged 60 and older has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Clofarabine (Clolar) (clofarabine)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Acute Myelogenous Leukemia | Phase 2 | Status: TERMINATED